Investigations concerning activator-free porcine plasmin. (Plasmin Novo)

Amris, C. J.; Amris, Annemarie

doi:10.1080/00365516309051331

Cited by 5 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After dialysis, Trasylol, 5 u/mi., was added to the reagent to inhibit fibrinolytic activity which has been variably found to contamninate different batches and which may affect the rate of thromboplastin formation (Amris, 1966). Activation product may be prepared in bulk, using the largest convenient quantity of starting plasma, for which fresh plasma, frozen plasma, and supematant plasma from which factor-VIII-rich cryoprecipitate has been prepared (Pool, Hershgold, and Pappenhagen, 1964), have all proved suitable.…”

Section: Preparation Of Reagentsmentioning

confidence: 99%

Diagnosis of haemophilia: use of an artificial factor-VIII-deficient human plasma system

Essien¹,

Ingram²

1967

Journal of Clinical Pathology

View full text Add to dashboard Cite

SYNOPSIS An artificial clotting system deficient in factor VIII has been made from normal human plasma. Factors XII and XI are supplied as 'activation product'. An eluate from AI(OH)3, which has beenincubated with normal plasma, supplies factors X and IX in their 'plasma' (unactivated) form with II. Factor V is provided as the supernatant after the Al(OH)3-treated plasma has been precipitated at one-third saturation with (NH4)2SO4. Fibrinogen is freed of factor VIII by freezing and thawing a lyophylized preparation and then added. Of these, activation product and the fibrinogen may be prepared in advance and stored frozen, and the eluate and supernatant may be made on the day of testing. A phospholipid source and CaCl2-solution are also required. In use, a patient's and a control plasma are first diluted in a mixture of the eluate, supernatant, and fibrinogen solution, and clotting times are recorded after completing the system by adding the phospholipid, activation product, and calcium chloride. The clotting times from the mixtures containing the patient's and the control plasmas may then be compared. (Biggs, Macfarlane, Denson, and Ash, 1965), the provision of Xa can presumably bypass a deficiency of VIII.

show abstract